Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Bengtsson

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Pharmaceutical Research|August 12, 2006
Effects of sodium taurocholate on the absorption of inhaled 99mTc-DTPAEva Bondesson, Thomas Bengtsson, Lars-Erik Nilsson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 28, 2020
Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed AnalysisHenrik Watz, Kathleen Rickard, Tara Rheault, et al.
Current Medical Research and Opinion|April 19, 2008
Relative systemic availability of budesonide in patients with asthma after inhalation from two dry powder inhalersGunnar Persson, Jaro Ankerst, Michael Gillen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2012
18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake valueThomas Bengtsson, Rodney J Hicks, Amy Peterson, et al.
Drug Design, Development and Therapy|February 25, 2015
Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA)Leif Bjermer, Piotr Kuna, Carin Jorup, et al.
Respiratory Medicine|March 15, 2005
Formoterol used as needed in patients with intermittent or mild persistent asthmaAlexandr Chuchalin, Milan Kasl, Thomas Bengtsson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 29, 2021
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium TherapyGary T Ferguson, Edward M Kerwin, Tara Rheault, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 3, 2023
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPDJames F Donohue, Tara Rheault, Margot MacDonald-Berko, et al.
EJNMMI Research|February 3, 2012
Quantitation of glucose uptake in tumors by dynamic FDG-PET has less glucose bias and lower variability when adjusted for partial saturation of glucose transportSimon-Peter Williams, Judith E Flores-Mercado, Ruediger E Port, et al.
Respiratory Research|February 12, 2020
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPDDave Singh, Fernando J Martinez, Henrik Watz, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Pharmaceutical Research|August 12, 2006
Effects of sodium taurocholate on the absorption of inhaled 99mTc-DTPAEva Bondesson, Thomas Bengtsson, Lars-Erik Nilsson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 28, 2020
Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed AnalysisHenrik Watz, Kathleen Rickard, Tara Rheault, et al.
Current Medical Research and Opinion|April 19, 2008
Relative systemic availability of budesonide in patients with asthma after inhalation from two dry powder inhalersGunnar Persson, Jaro Ankerst, Michael Gillen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2012
18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake valueThomas Bengtsson, Rodney J Hicks, Amy Peterson, et al.
Drug Design, Development and Therapy|February 25, 2015
Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA)Leif Bjermer, Piotr Kuna, Carin Jorup, et al.
Respiratory Medicine|March 15, 2005
Formoterol used as needed in patients with intermittent or mild persistent asthmaAlexandr Chuchalin, Milan Kasl, Thomas Bengtsson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 29, 2021
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium TherapyGary T Ferguson, Edward M Kerwin, Tara Rheault, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 3, 2023
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPDJames F Donohue, Tara Rheault, Margot MacDonald-Berko, et al.
EJNMMI Research|February 3, 2012
Quantitation of glucose uptake in tumors by dynamic FDG-PET has less glucose bias and lower variability when adjusted for partial saturation of glucose transportSimon-Peter Williams, Judith E Flores-Mercado, Ruediger E Port, et al.
Respiratory Research|February 12, 2020
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPDDave Singh, Fernando J Martinez, Henrik Watz, et al.
Pageof 7